Celator Pharmaceuticals Inc

Celator Pharmaceuticals — Corporate Update (December 2014)

62 slides from Celator Pharmaceuticals's corporate update, Dec 8, 2014

  1. Slide 1: Corporate Update December 6, 2014

    ® Corporate Update December 6, 2014 ®

  2. Slide 2: Safe Harbor

    ® SAFE HARBOR To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Secur

  3. Slide 3: Agenda

    ® AGENDA 8:00 – 8:10 pm: Welcome & Introduction Scott Jackson Chief Executive Officer 8:10 – 8:20 pm: CombiPlex Update & Review of CPX - 351 Preclinical Data Selected for Presentation at the American Society of Hematology meeting Dr. Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Office

  4. Slide 4: Welcome & Introduction

    ® 4 Welcome & Introduction Scott Jackson Chief Executive Officer

  5. Slide 5: Our Mission: To Improve and Extend the Lives of Patients with Cancer

    ® OUR MISSION: TO IMPROVE AND EXTEND THE LIVES OF PATIENTS WITH CANCER BY TRANSFORMING THE SCIENCE OF COMBINATION THERAPY 5

  6. Slide 6: Developing Cutting Edge Technologies for Cancer Treatment

    ® DEVELOPING CUTTING EDGE TECHNOLOG IES FOR CANCER TREATMENT • CombiPlex ® is a combination - optimizing technology platform • Elevated, prolonged, selective exposure of synergistic drug ratios to tumors • Broadening applications for CombiPlex • Evaluating 3 novel targeted combination products, that

  7. Slide 7: Celator's Proprietary Oncology Pipeline

    ® 7 CELATOR’S PROPRIETARY ONCOLOGY PIPELINE CPX - 1 Irinotecan:Floxuridine CPX - 351 Cytarabine:Daunorubicin CPX - 8 (HDPN) Taxane Nanoparticle Research Preclinical Phase 1 Phase 2 Proprietary Technology Platforms Phase 3 Colorectal Cancer Secondary Acute Myeloid Leukemia (Ongoing) Solid Tumors Nove

  8. Slide 8: Building a Broad Pipeline from the CombiPlex Platform

    ® BUILDING A BROAD PIPELINE FROM THE COMBIPLEX ® PLATFORM • Advancing CombiPlex to widen its application to molecularly targeted therapies • Combinations targeting signaling pathways (i.e. inhibitors of PI3K/AKT/ mTOR pathway and inhibitors of Ras / Raf /MEK/ERK pathway) • Combinations of existing c

  9. Slide 9: Phase 3 Study Design in sAML

    ® 9 CPX - 351 PHASE 3 STUDY DESIGN IN S AML STUDY ACHIEVED TARGET ENROLLMENT AHEAD OF SCHEDULE Eligibility • Confirmation of sAML according to the World Health Organization (WHO) criteria with certain exclusions • Age 60 - 75 years • Able to tolerate intensive chemo • PS 0 - 2 Randomization CPX - 35

  10. Slide 10: Advantages of the Phase 3 Study

    ® ADVANTAGES OF THE CPX - 351 PHASE 3 STUDY 10 • AML is heterogeneous • Single arm studies used to design Phase 3 studies may not be predictive • Two randomized, controlled clinical studies were conducted to identify patient populations to pursue in Phase 3; initial registration study is in sAML pat

  11. Slide 11: Advantages of the Phase 3 Study

    ® • Benefit seen with CPX - 351 vs 7+3 is consistent across all metrics – higher response rate, reduced early mortality and improved overall survival • A positive Phase 3 result can be achieved with half the overall survival observed in the Phase 2 (the population that matches the eligibility being

  12. Slide 12: Selected Phase 3 AML Product Candidates

    ® SELECTED PHASE 3 AML PRODUCT CANDIDATES Celator (CPXX) Sunesis (SNSS) Cyclacel (CYCC) Ambit (AMBI) Product CPX - 351 vosaroxin (Qinprezo) sapacitabine quizartinib Patient Population secondary AML >60 and <75 years of age Relapsed/refractory AML > 18 years of age First - line >70 years of age FLT3

  13. Slide 13: CombiPlex Update & Preclinical Data Being Presented at ASH

    ® 13 CombiPlex ® Update & CPX - 351 Preclinical Data Being Presented at ASH Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Officer

  14. Slide 14: CombiPlex: Rationale for Role of Drug Delivery in Targeted Combinations

    ® COMBIPLEX®: RATIONALE FOR ROLE OF DRUG DELIVERY IN DEVELOPMENT OF TARGETED AGENT COMBINATIONS 14 Conventional Combinations CombiPlex ® Many require simultaneous target inhibition Harmonized PK and tumor cell exposure to both agents Toxicity complications observed with many targeted agent combinati

  15. Slide 15: Combinations Identified for CombiPlex Application to Targeted Agents

    ® COMBINATIONS IDENTIFIED FOR COMBIPLEX ® APPLICATION TO MOLECULARLY TARGETED AGENTS Histone deacetylase inhibitors plus Hypomethylating agents • Promising early clinical evidence of favorable interaction • Optimal efficacy with simultaneous exposure • Dose limiting toxicity (encephalopathy) of comb

  16. Slide 16: CombiPlex May Address Shortcomings for Targeted Combinations

    ® COMBIPLEX ® MAY ADDRESS A VARIETY OF SHORTCOMINGS FOR MOLECULARLY TARGETED COMBINATIONS UNDER INVESTIGATION 16 ISSUE CombiPlex ® PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK Docetaxel ) plus HSP90 inhibitors HDAC inhibitors plus Hypomethylating agents Pathway cross - talk requires concurrent inhibition

  17. Slide 17: CombiPlex May Address Shortcomings for Targeted Combinations

    ® COMBIPLEX ® MAY ADDRESS A VARIETY OF SHORTCOMINGS FOR MOLECULARLY TARGETED COMBINATIONS UNDER INVESTIGATION 17 ISSUE CombiPlex ® PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK Docetaxel ) plus HSP90 inhibitors HDAC inhibitors plus Hypomethylating agents Pathway cross - talk requires concurrent inhibition

  18. Slide 18: CombiPlex May Address Shortcomings for Targeted Combinations

    ® COMBIPLEX ® MAY ADDRESS A VARIETY OF SHORTCOMINGS FOR MOLECULARLY TARGETED COMBINATIONS UNDER INVESTIGATION 18 PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK Docetaxel ) plus HSP90 inhibitors HDAC inhibitors plus Hypomethylating agents Pathway cross - talk requires concurrent inhibition for optimal effica

  19. Slide 19: Prodrug Nanoparticle Formulation Increases Plasma Drug Concentration

    ® Hours After Administration 0 5 10 15 20 25 Percent Injected Dose 0.0001 0.001 0.01 0.1 1 10 100 1000 Docetaxel prodrug AUY922 prodrug Free AUY922 Free Docetaxel 19 PRODRUG NANOPARTICLE FORMULATION OF DOCETAXEL AND AUY922 DRAMATICALLY INCREASE PLASMA DRUG CONCENTRATION Plasma concentrations of AUY9

  20. Slide 20: American Society of Hematology Poster Presentations

    ® American Society of Hematology Poster Presentations 20

  21. Slide 21: CPX-351: ADME (Absorption, Distribution, Metabolism and Excretion)

    ® CPX - 351: ADME (ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION) • CPX - 351 Markedly Reduces Renal and Hepatic Clearance Rates for Cytarabine ( Cyt ) and Daunorubicin ( Daun ) in Rats with an Associated Decrease in Excretory and Metabolic Burden Despite Providing Dramatic Increases in Systemi

  22. Slide 22: Slower Drug Elimination Reduces Burden on Excretory/Metabolic Systems

    ® SLOWER DRUG ELIMINATION FOR CPX - 351 COMPARED TO FREE DRUGS REDUCES BURDEN ON EXCRETORY / METABOLIC SYSTEMS 22 DAUNORUBICIN CYTARABINE

  23. Slide 23: QWBA Reveals Decreased Distribution and Bone Marrow Accumulation: Cytarabine

    ® QWBA REVEALS DECREASED DRUG DISTRIBUTION TO MOST TISSUES AND INCREASED ACCUMULATION IN BONE MARROW CYTARABINE Treatment Hours after Administration [ 14 C]Cytarabine 1 24 Non-Liposomal CPX-351 23

  24. Slide 24: QWBA Reveals Decreased Distribution and Bone Marrow Accumulation: Daunorubicin

    ® QWBA REVEALS DECREASED DRUG DISTRIBUTION TO MOST TISSUES AND INCREASED ACCUMULATION IN BONE MARROW 24 DAUNORUBICIN Treatment Hours after Administration [ 14 C]Daunorubicin 1 48 Non-Liposomal CPX-351

  25. Slide 25: Conclusions from Preclinical ADME

    ® CONCLUSIONS FROM PRECLINICAL ADME • The slower drug excretion of Cyt and Daun for CPX - 351 suggests that the burden on excretory and metabolic systems may be reduced for CPX - 351 • CPX - 351 limits early tissue distribution of Cyt and Daun compared to the drugs administered as the non - liposoma

  26. Slide 26: CPX-351 Update

    ® CPX - 351 UPDATE DR. JEFFREY LANCET SECTION CHIEF OF LEUKEMIA, DEPARTMENT OF MALIGNANT HEMATOLOGY, MOFFITT CANCER CENTER 26

  27. Slide 27: Timeline of Progress in AML

    ® Timeline of “progress” in AML 1950s - 1960s 1970s 1980s 1990s 2000s 2010s Daunorubicin Cytarabine Daunorubicin + Cytarabine Idarubicin + Cytarabine High - dose Cytarabine Gemtuzumab Cladribine Vosaroxin CPX - 351 Sapacitabine Midostaurin HMAs HDAC inhibitors 27

  28. Slide 28: AML Survival in Older Patients

    ® AML survival: patients ≥ 60 years Burnett et al. Semin Hematol 2006: 43(2):96 - 106 0 1 2 3 4 5 6 7 8 0.0 0.2 0.4 0.6 0.8 1.0 Years Survival Probability 28

  29. Slide 29: Issues Delaying Development of Effective New Therapy in AML

    ® Issues delaying the development of effective new therapy in AML • Discovery of molecular anomalies have not yet translated into clear therapeutic targets • Lack of molecular data applied retrospectively to predict response • Trial Design • Empiric testing in a heterogeneous disease • Especially wi

  30. Slide 30: CPX-351 Liposome Composition

    ® CPX - 351 • 100 nm bilamellar liposomes • 5:1 molar ratio of cytarabine to daunorubicin • 1 unit = 1.0 mg cytarabine plus 0.44 mg daunorubicin 30

  31. Slide 31: Pharmacological Basis of CPX-351

    ® Pharmacological Basis of CPX - 351 CPX - 351 liposome delivers 5:1 molar ratio for >24 hours Hours After Administration 0 20 40 60 80 100 120 140 160 180 Bone Marrow Cytarabine (  g/ml) 0 1 2 3 CPX-351 Free drug cocktail Cytarabine Accumulates and persists in the bone marrow Preferential uptake a

  32. Slide 32: Phase 1 Study of CPX-351 in AML

    ® Phase 1 study of CPX - 351 in AML • First in human study • Relapsed, refractory AML • Dose escalation – planned up to 134 units/m 2 • Primary endpoints – safety, maximum tolerated dose 32

  33. Slide 33: Phase 1 Study: Key Findings

    ® Phase 1 study of CPX - 351 in AML: Key Findings • Safety • Dose limiting toxicity in 3 of 6 patients at 134 units/m 2 • Congestive heart failure, hypertension, prolonged cytopenias • Other most common grade 3 - 4 toxicities • Rash, liver function abnormalities, • Clinical congestive heart failure

  34. Slide 34: Pharmacokinetics

    ® Pharmacokinetics 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 0 24 48 72 96 120 144 168 TIME (hr) Cytarabine Daunorubicin Mean plasma concentration after the day 5 infusion among patients receiving 24 units/m^2 CPX-351 (n=3) D & A detectable 7 days at completion of infusion Fixed molar ra

  35. Slide 35: Randomized Phase 2 Trial vs 7+3 in Older Untreated AML

    ® Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Eligibility • Newly diagnosed • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 (n=85) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 (n=41) Daunorubicin 60 mg/m 2 Cytarabine 100

  36. Slide 36: Key Demographic Features

    ® Key Demographic Features CPX - 351 7+3 n=85 n=41 Gender Male 53 (62.4%) 25 (61.0%) Race Caucasian 76 (89.4%) 39 (95.1%) Risk Standard Risk 28 (32.9%) 14 (34.1%) High Risk 57 (67.1%) 27 (65.9%) Age Group ≥70yrs 34 (40.0%) 15 (36.6%) Median (yrs) 68.0 68.0 AML Type De novo AML 52 (61.2%) 22 (53.7%)

  37. Slide 37: Randomized Phase 2 Trial Results vs 7+3

    ® Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Parameter CPX - 351 (n=84) “7+3” Regimen (n=41) CR (%) 41 (48.8) 20 (48.8) CRi (%) 15 (17.9) 1 (2.4) CR + CRi (%) 56 (66.6) 21 (51.2) 60 - d mortality (%) 4 (4.7) 6 (14.6) CR + CRi (%) in s - AML 19 (57.5) 6 (31.6) s - AML media

  38. Slide 38: Overall Survival by Treatment Arm

    ® Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Lancet et al, Blood 2014; 123:3239 sAML All Patients Overall Survival Overall Survival by treatment arm 0% 20% 40% 60% 80% 100% 0 12 24 36 48 Months from randomization Arm A: CPX - 351 Arm B: 7+3 Deaths / N 58 / 85 27 / 41 Media

  39. Slide 39: Safety

    ® Safety CPX - 351 (n=85) 7+3 (n=41) n (%) n (%) Grade 3/4 Grade 5 Grade 3/4 Grade 5 Febrile Neutropenia 54 (63.5) 0 (0.0) 21 (51.2) 0 (0.0) Infections 60 (70.6) 3 (3.5) 18 (43.9) 3 (7.3) Bacteraemia 30 (35.3) 0 (0.0) 8 (19.5) 0 (0.0) Epistaxis 6 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) Petechiae 1 (1.2) 0 (0.

  40. Slide 40: Outcomes in Patients with Prior Hypomethylating Agent Exposure

    ® Outcomes in patients with prior hypomethylating agent exposure Prior Hypomethylating Agent Treatment CPX - 351 n=33 (%) 7+3 n=19 (%) +HMA 13 (39%) - HMA 20 (61%) +HMA 7 (37%) - HMA 12 (63%) Responses 7 (54) 12 (60) 2 (29) 4 (33) CR 3 (23) 9 (45) 2 (29) 4 (33) CRi 4 (31) 3 (15) 0 0 40

  41. Slide 41: Randomized Phase 2 Trial vs Salvage in 1st Relapse AML

    ® Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Eligibility • 1st Relapse • Initial CR ≥1 month • Ages 18 - 65 • Stratified by European Prognostic Index • PS 0 - 2 CPX - 351 (n=81) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations Salvage (as per investigat

  42. Slide 42: Phase 2 Relapse AML Results

    ® Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Overall (n=125) EPI Poor - Risk ( n=85) CPX - 351 (n=81) Salvage (n=44) CPX - 351 (n=56) Salvage (n=29) Response Rate 49.4% 40.9% 39.3% 27.6% 60 - Day Mortality 14.8% 15.9% 16.1% 24.1% EFS (median, mos.) 4.0 1.4 1.9 1.2 OS (media

  43. Slide 43: Potential Reasons for Greater Benefit in High-Risk AML

    ® Potential reasons why CPX - 351 has a greater benefit in High - Risk AML Patients • Altered signaling/cell cycle control checkpoints • 5:1 molar ratio: constant cytarabine excess → daunorubicin DNA damage without blocking cell cycle progression to S - phase where cytarabine action occurs preventin

  44. Slide 44: Randomized Phase 3 Trial vs 7+3 in Older Patients with sAML

    ® Randomized Phase 3 Trial of CPX - 351 vs “7+3” in Older Patients with sAML Eligibility • Previously untreated sAML or tAML • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 Daunorubicin 60 mg/m 2 Cytar

  45. Slide 45: Phase II sAML Definition: Phase II vs. Phase III

    ® CPX - 351 vs 7+3 Phase II study: sAML Definition Phase II vs. Phase III *Patient 12 - 004, originally identified as a de novo patient, was diagnosed with Philadelphia chromosome and was not assessed for response Phase III study will use WHO criteria for confirmation of secondary AML 16 patients ad

  46. Slide 46: What Makes AML-301 Unique from Other Phase 3 AML Studies

    ® What makes AML - 301 unique from other phase 3 AML studies? • Based upon a prior randomized study • Based upon a prior study that identified a distinct group of patients found to benefit from CPX - 351 (secondary AML) • Primary endpoint (overall survival) was modeled upon the primary endpoint from

  47. Slide 47: Endpoints

    ® Endpoints • Primary • Overall survival with >90% power to detect HR = 0.63 • Detect a 37% decrease in the rate of death with CPX - 351 over the course of the study. • Secondary • Response rate (CR+CRi) • Event - free survival • 60 day mortality • Leukemia clearance rate 47

  48. Slide 48: Power Calculations

    ® Power Calculations Power Hazard Ratio 70 0.726 75 0.712 80 0.697 85 0.679 90 0.657 93.7 0.635 Arm B Rate 31% 42% Power Arm A Rate (%) Difference (%) Arm A Rate (%) Difference (%) 70 46.5 15.5 57.9 15.9 75 47.4 16.4 58.8 16.8 80 48.4 17.4 59.8 17.8 85 49.6 18.6 60.9 18.9 90 51.0 20.0 62.3 20.3 95 5

  49. Slide 49: Final Induction Response Rate Analysis

    ® Final Induction Response Rate Analysis • When: • 2Q 2015 • What: • CPX - 351 CR+Cri /n (%) vs. Control CR+CRi /n (%) • No p - value will be calculated • Comments: • Final induction response rate analysis was prospectively defined in the Phase 3 protocol and statistical analytical plan • The analys

  50. Slide 50: Secondary AML Patient Population Response Rate

    ® Secondary AML Patient Population Response Rate n=58 CPX - 351 (n=39) 7+3 (n=19) CR+CRi 1 (%) 73.7 42.1 CR only 1 (%) 50.0 42.1 CRi only 1 (%) 23.7 0 1 Patient 12 - 004, originally identified as a de novo patient, was diagnosed with Philadelphia chromosome and was not assessed for response 50

  51. Slide 51: Secondary AML Patient Population Early Mortality

    ® Secondary AML Patient Population Early Mortality n=58 CPX - 351 (n=39) 7+3 (n=19) Early mortality (d=60) (%) 2.6 26.3 51

  52. Slide 52: Secondary AML Patient Population Median Overall Survival

    ® Secondary AML Patient Population Median Overall Survival n = 58 CPX - 351 ( n=39 1 ) 7+3 (n=19 2 ) All Patients 12.1 months 6.3 months Responders 15.4 months (n=28) 9.4 months (n=8) Non Responders 9.2 months 3.2 months 1 Patient 12 - 004, originally identified as a de novo patient, was diagnosed w

  53. Slide 53: Secondary AML Summary of Important Endpoints

    ® Secondary AML Patient Population Summary of Important Endpoints n = 58 CPX - 351 ( n=39 1 ) 7+3 (n=19 2 ) Morphologic Leukemia Free State 3 35/39 (89.7%) 12/17 (70.6%) Response Rate ( CR+CRi ) (%) 73.7 42.1 Duration of Remission (Months) 6.2 4.3 60 Day Mortality (%) 2.6 26.3 Median Event Free Surv

  54. Slide 54: American Society of Hematology Poster Presentations

    ® American Society of Hematology Poster Presentations 54

  55. Slide 55: CPX-351: HR-MDS or AML Patients at High Risk of Treatment-Related Mortality

    ® CPX - 351: HR - MDS OR AML PATIENTS AT HIGH - RISK OF TREATMENT - RELATED MORTALITY • Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX - 351) for Adults with Untreated High - Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment - Related Mort

  56. Slide 56: HR-MDS or AML Patients at High Risk of Treatment-Related Mortality

    ® • Patients with AML/MDS at high risk of early mortality following treatment are often given palliative care with no serious attempt to induce remissions. • These patients are heterogeneous and causes of early mortality include progressive AML/MDS and treatment - induced toxicities. • The TRM scori

  57. Slide 57: HR-MDS or AML Patients at High Risk of Treatment-Related Mortality

    ® • Patients were randomized to receive CPX - 351 at 32 or 64 units/m2 by 90 - minute infusion on days 1, 3, and 5. • The 64 unit/m2 dose level observed 3 early deaths and 2 CR among 9 patients. • Based on a comparison with historic controls who principally received 7+3 or high - dose cytarabine - b

  58. Slide 58: Question & Answer Session

    ® Question & Answer Session 58

  59. Slide 59: Closing Remarks

    ® Closing Remarks SCOTT JACKSON CHIEF EXECUTIVE OFFICER 59

  60. Slide 60: Creating Shareholder Value

    ® CREATING SHAREHOLDER VALUE • Execution of the Phase 3 study and preparation for regulatory submission and commercialization • Celator to commercialize CPX - 351 in the US • Seek ex - US partner • Continue to evaluate the potential of CPX - 351 in other patient populations (e.g. AML and other hemat

  61. Slide 61: 2014-2016 Expected Milestones

    ® 2014 - 2016 EXPECTED MILESTONES POTENTIAL NDA FILING FOR CPX - 351 IN 2H2016 Phase 3 Remission Rate Start Technology Platform Programs Phase 3 Overall Survival Complete Technology Platform Programs NDA Submission 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 2014 2015 2016 First Relapse Phase 2 Publication ASH

  62. Slide 62: Thank You

    ® 62 THANK YOU!!!

Celator Pharmaceuticals — Corporate Update (December 2014) on 6ix